Our story began in 2012, when a team composed of experienced consultants, leaders from the pharmaceutical industry and researchers from Uppsala University formed Pharmetheus, a pharmacometric consultancy services with the overall aim to improve patients’ lives. Since that time our core business focus has broadened to support a wider range of model informed drug development (MIDD) activities across all phases of research and development and across a wide range of therapeutic areas. We continue to provide fit for purpose analyses and reports to support a wide variety of drug development decisions (such as dose selection, developing pediatric development plans, investigating the potential risk for QTc prolongation etc.). Read more at www.pharmetheus.com